The Australian government announced last week there's a new vaccine for pneumococcal disease on the National Immunization ...

Merck (MRK) stock in focus as the company posts late-stage trial data to indicate that its Capvaxive pneumonia vaccine is ...

Results from the Phase 3 STRIDE-13 trial presented at the 6th ESCMID Conference on VaccinesMerck to share STRIDE-13 results with global regulatory authoritiesRAHWAY, N.J.--(BUSINESS WIRE)--$MRK ...

CINCINNATI, Oct. 11, 2022 (GLOBE NEWSWIRE) -- Blue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or the “Company”), a biopharmaceutical company developing transformational vaccines to address ...

Merck announces positive results from phase 3 STRIDE-13 trial of Capvaxive to treat pneumococcal disease: Rahway, New Jersey Friday, September 12, 2025, 10:00 Hrs [IST] Merck, kno ...

Initiation of a first-in-man Phase I clinical trial in healthy subjects Study aims to obtain safety and immunogenicity data of this new vaccine candidate Initial results expected in Q4 2009 ...

In a recent study posted to the medRxiv* preprint server, researchers investigate the effect of colonization of the upper respiratory tract (URT) by Streptococcus pneumoniae on severe acute ...

In a recent study posted to the medRxiv* preprint server, researchers from Germany conducted a population-based surveillance study to ascertain the etiology of community-acquired pneumonia (CAP) ...

Janine Zahlten, Ye-Ji Kim, Jan-Moritz Doehn, Thomas Pribyl, Andreas C. Hocke, Pedro García, Sven Hammerschmidt, Norbert Suttorp, Stefan Hippenstiel, Ralf-Harto ...

- Development of Intercell's Streptococcus pneumoniae vaccine supported by PATH VIENNA, April 7 /PRNewswire/ -- Intercell AG (VSE: ICLL) announced today that a Phase I clinical trial with the ...